Aberrant processing of Fas transcripts in adult T-cell leukemia: a possible role in tumor cell survival.

[1]  G. Fiucci,et al.  Detection of polymorphisms within the FAS cDNA gene sequence by GC-clamp denaturing gradient gel eletrophoresis , 2004, Immunogenetics.

[2]  D. Katsaros,et al.  Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer , 2001, British Journal of Cancer.

[3]  S Rosenberg,et al.  Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. , 2001, Cancer research.

[4]  A. Puisieux,et al.  p53 induction prevents accumulation of aberrant transcripts in cancer cells. , 2001, Cancer research.

[5]  R. Willemze,et al.  High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. , 2000, Blood.

[6]  H. Sakaguchi,et al.  Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. , 2000, Immunology letters.

[7]  J. McCune,et al.  A Membrane-bound Fas Decoy Receptor Expressed by Human Thymocytes* , 2000, The Journal of Biological Chemistry.

[8]  M. Tomonaga,et al.  Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO‐1) in adult T‐cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis , 1999, British journal of haematology.

[9]  J. Bajorath.  Identification of the ligand binding site in Fas (CD95) and analysis of Fas‐ligand interactions , 1999, Proteins.

[10]  M. Tomonaga,et al.  Fas Gene Mutation in the Progression of Adult T Cell Leukemia , 1999, The Journal of experimental medicine.

[11]  M. Matsuoka,et al.  Mutation of CD95 (Fas/Apo-1) Gene in Adult T-Cell Leukemia Cells , 1998 .

[12]  Lin Jin,et al.  Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis , 1998, Neuron.

[13]  D. Darmer,et al.  Alternative splicing of the primary Fas transcript generating soluble Fas antagonists is suppressed in the failing human ventricular myocardium. , 1997, Biochemical and biophysical research communications.

[14]  M. Tomonaga,et al.  Soluble and membrane isoforms of Fas/CD95 in fresh adult T‐cell leukemia (ATL) cells and ATL‐cell lines , 1997, International journal of cancer.

[15]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[16]  M. Raff,et al.  Programmed Cell Death in Animal Development , 1997, Cell.

[17]  G. Starace,et al.  An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. , 1996, Journal of immunology.

[18]  R. Testi,et al.  Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. , 1996, Journal of immunology.

[19]  J. Mountz,et al.  Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. , 1995, The Biochemical journal.

[20]  T. Kotani,et al.  Expression of functional Fas antigen on adult T-cell leukemia. , 1994, Leukemia research.

[21]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[22]  T. Waldmann,et al.  APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. , 1993, Blood.

[23]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[24]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[25]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.